| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OS9 |
| Uniprot No | Q13438 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-612aa |
| 氨基酸序列 | MAAETLLSSLLGLLLLGLLLPASLTGGVGSLNLEELSEMRYGIEILPLPV MGGQSQSSDVVIVSSKYKQRYECRLPAGAIHFQREREEETPAYQGPGIPE LLSPMRDAPCLLKTKDWWTYEFCYGRHIQQYHMEDSEIKGEVLYLGYYQS AFDWDDETAKASKQHRLKRYHSQTYGNGSKCDLNGRPREAEVRFLCDEGA GISGDYIDRVDEPLSCSYVLTIRTPRLCPHPLLRPPPSAAPQAILCHPSL QPEEYMAYVQRQADSKQYGDKIIEELQDLGPQVWSETKSGVAPQKMAGAS PTKDDSKDSDFWKMLNEPEDQAPGGEEVPAEEQDPSPEAADSASGAPNDF QNNVQVKVIRSPADLIRFIEELKGGTKKGKPNIGQEQPVDDAAEVPQREP EKERGDPERQREMEEEEDEDEDEDEDEDERQLLGEFEKELEGILLPSDRD RLRSEVKAGMERELENIIQETEKELDPDGLKKESERDRAMLALTSTLNKL IKRLEEKQSPELVKKHKKKRVVPKKPPPSPQPTGKIEIKIVRPWAEGTEE GARWLTDEDTRNLKEIFFNILVPGAEEAQKERQRQKELESNYRRVWGSPG GEGTGDLDEFDF |
| 预测分子量 | 96 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OS9重组蛋白的3篇示例参考文献(内容为模拟生成，供参考)：
---
1. **文献名称**：*OS9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to regulate oxygen-dependent degradation of misfolded proteins*
**作者**：Hosokawa, N., et al.
**摘要**：研究揭示了OS9通过结合缺氧诱导因子1α(HIF-1α)和脯氨酰羟化酶(PHDs)，参与氧依赖性错误折叠蛋白的识别与降解，为内质网质量控制(ERQC)机制提供了新见解。
2. **文献名称**：*Structural basis for the recognition of misfolded proteins by the OS9-XTP3-B ERAD complex*
**作者**：Christianson, J.C., et al.
**摘要**：通过X射线晶体学解析OS9与XTP3-B复合物结构，阐明其识别带有高甘露糖聚糖的错误折叠蛋白的分子机制，揭示了OS9在内质网相关降解(ERAD)中的关键作用。
3. **文献名称**：*OS9 promotes hepatocellular carcinoma metastasis by modulating EGFR degradation via the ERAD pathway*
**作者**：Li, Y., et al.
**摘要**：研究发现OS9通过ERAD途径调控表皮生长因子受体(EGFR)的稳定性，促进肝癌细胞侵袭转移，为靶向OS9的癌症治疗提供了潜在策略。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词(如“OS9 recombinant protein”“ERAD OS9”)获取最新研究。
**Background of OS9 Recombinant Protein**
OS9 (Osteosarcoma amplified 9) is an endoplasmic reticulum (ER)-resident glycoprotein initially identified due to its amplification in osteosarcoma. It plays a critical role in ER-associated degradation (ERAD), a quality control pathway that identifies and directs misfolded proteins for proteasomal degradation. OS9 acts as a key adaptor, recognizing terminally misfolded glycoproteins via interactions with their high-mannose oligosaccharides. This recognition facilitates their recruitment to the ERAD machinery, including the Hrd1-SEL1L ubiquitin ligase complex.
Structurally, OS9 contains a mannose-6-phosphate receptor homology (MRH) domain essential for glycan binding and a conserved OS9 domain involved in protein-protein interactions. Its ability to bind both misfolded substrates and ERAD components underscores its role as a bridge in substrate targeting. Recombinant OS9 protein, produced using expression systems like *E. coli* or mammalian cells, retains these functional properties, enabling in vitro studies of ERAD mechanisms.
Research leveraging recombinant OS9 has advanced understanding of diseases linked to protein misfolding, such as neurodegenerative disorders (e.g., Alzheimer’s) and cancers. For instance, OS9 overexpression in tumors may promote survival under ER stress, suggesting therapeutic targeting potential. Additionally, OS9 interacts with hypoxia-inducible factors (HIFs), implicating it in cellular responses to low oxygen, a feature exploited by fast-growing tumors.
Overall, OS9 recombinant protein serves as a vital tool for dissecting ERAD pathways, modeling disease mechanisms, and screening compounds aimed at modulating proteostasis. Its study continues to reveal insights into cellular stress responses and opportunities for therapeutic intervention.
×
